同伴陪伴式关系减害干预对无家可归与物质使用问题人群心理健康、生活质量及相关结局的有效性与成本效果:SHARPS整群随机对照试验方案
SHARPS可行性研究显示同伴导航员可改善无家可归与物质使用问题人群的服务参与、阿片替代治疗可及性并减少吸毒与危险注射行为。本方案为双臂实用型整群随机对照试验,在20个集群中1:1随机分配至同伴陪伴式减害干预组或常规社会照护组,目标样本550人,主要结局为心理健康与生活质量,并评估成本效果。
要点
- 同伴导航员的亲身经历有助于建立信任关系,可行性研究已显示可改善服务参与并减少危险注射行为。
- 本试验为双臂实用型整群随机对照试验,20个集群按1:1随机分配,目标样本共550人。
- 共同主要结局为心理健康与生活质量,同时评估增量成本每QALY与每YFC及成本后果分析。
核心结论
- 试验结果将用于判断SHARPS干预对无家可归与物质使用问题人群是否有积极影响,以及在英国社会照护服务中推广是否具有成本效果。
- 该干预为共同设计、同伴陪伴、减害与关系性干预,持续12个月。
研究设计与样本
- 双臂、实用型、整群随机对照试验,嵌入成本效果评价与混合方法过程评价。
- 招募对象为年龄超过18岁、正在经历或有无家可归风险且自报有物质使用问题、并接受救世军(The Salvation Army,TSA)无家可归服务者,覆盖20个纳入集群(城镇/城市)。
- 每个集群按1:1随机分配至干预组或对照组,采用基于区域层面特征的协变量约束分配。
- 目标样本量为总共550名参与者。
- 干预组接受共同设计的同伴陪伴式减害关系性干预,持续12个月;对照组接受由TSA支持工作者在无家可归服务内提供的常规社会照护。
主要发现
- SHARPS可行性研究表明同伴导航员可帮助改善服务参与、增加阿片替代治疗可及性,并减少吸毒与危险注射行为。
- 可行性研究参与者指出,同伴导航员的亲身经历通过促成信任关系的建立而特别有帮助。
- 共同主要结局为心理健康与生活质量;次要结局包括有害物质使用、冒险行为、社会功能、身体健康、社会结局、住房状况、治疗联盟/可及性、服务利用与关系性共情。
- 数据收集点为基线、6个月与12个月,主要感兴趣时间点为基线测量后12个月。
- 经济结局为干预相对于标准无家可归服务照护的增量成本每质量调整生命年(QALY)与每完全能力年(YFC),涵盖NHS、地方政府、刑事司法及第三部门主办组织的成本;分别使用EQ-5D-5L与ICECAP-A计算QALY与YFC,并将进行成本后果分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Those experiencing homelessness and problem substance use find it challenging to access the healthcare and treatment they need. The Supporting Harm Reduction through Peer Support (SHARPS) feasibility study demonstrated that Peer Navigators can help these individuals to improve their service engagement, increase access to opioid substitution therapy, and lead to reductions in drug use and risky injection practices. Specifically, participants indicated that the lived experience of Peer Navigators was particularly helpful by enabling the development of trusting relationships. A cluster randomised controlled trial (cRCT) will now assess the effectiveness and cost-effectiveness of a Peer Navigator intervention with this population. METHODS: A two-arm, pragmatic, cRCT will be conducted with embedded cost-effectiveness and mixed methods process evaluations. Individuals will be recruited who are as follows: over the age of 18 years; experiencing/at risk of homelessness and self-report problem substance use; and attending The Salvation Army (TSA) homelessness services across 20 included clusters (towns/cities). Each cluster will be randomised (1:1) to either the intervention or control arm using covariate-constrained allocation based on area-level characteristics. The target sample size is 550 participants in total. A co-produced peer-delivered harm reduction, relational intervention lasting 12 months will be delivered to those in the intervention arm. Usual care will be social care via TSA Support Workers delivered within homelessness services. The co-primary outcomes will be mental health and quality of life, with harmful substance use, risk taking behaviours, social functioning, physical health, social outcomes, housing status, therapeutic alliance/accessibility, service utilisation, and relational empathy chosen as secondary outcomes. Data collection points are baseline, 6 and 12 months, for all measures. The primary timepoint of interest is 12 months after baseline measurement. Economic outcomes will be incremental cost per quality-adjusted life year (QALY) and per year in full capability (YFC) gained with the intervention versus standard homelessness service care, inclusive of costs to the NHS, local government and criminal justice, and the third-sector host organisation. The EQ-5D-5L and ICECAP-A will be used to calculate QALYs and YFC respectively. We will also conduct a cost-consequence analysis. DISCUSSION: The results of this trial will be used to inform whether the SHARPS intervention has a positive impact on those experiencing homelessness and problem substance use and if it is cost-effective to roll it out across social care services. TRIAL REGISTRATION: ISRCTN11094645 ( https://doi.org/10.1186/ISRCTN11094645 , registered April 5, 2024).
引用
- Parkes T, Carver H, Boyd J, et al. Effectiveness and cost-effectiveness of a peer-delivered, relational, harm reduction intervention to improve mental health, quality of life, and related outcomes, for people experiencing homelessness and substance use problems: protocol for the 'SHARPS' cluster randomised controlled trial. Trials. 2025. PMID: 41390727. doi:10.1186/s13063-025-09364-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。